You are here

P&T News

September 26

Illegally marketed opioids are among the products targeted
Risk increases shortly after quitting and does not appear to diminish over time
Failure adds to the “slew” of 5-HT6 receptor antagonists abandoned in late-stage trials

September 25

Complete response letter issued to Intellipharmaceutics
In trial, 14.3% of patients responded to the drug
New indication targets advanced cases with PD-L1 expression
Prosecutors: Juxtapid marketed too broadly and investors misled

September 22

Patients with impaired liver function receiving too many doses

September 21

GOP takes heavy fire over pre-existing conditions
FDA and some companies dispute findings of report in NEJM
Benefits of opioid addiction treatment outweigh risks of adverse effects
Those in development are at best short-term solutions

September 20

Easier-to-clean Pentax device may help limit bacterial infections

September 19

First once-daily, single-inhaler triple therapy for the disease in the U.S.
Such drugs often block the serotonin that other organs need
Proprietary delivery system deposits proven steroid deep into the nose
Patient deaths related to other combination therapies concern the agency
Detailed procedures aim to protect patients from promising treatment’s toxicities

September 18

PFS worse with bendamustine and rituximab in new study

Pages